Skip to main content
SpringerLink
Log in

Treatment of Convulsive Status Epilepticus

  • Epilepsy (E Waterhouse, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Convulsive status epilepticus (CSE) is a medical emergency with an associated high mortality and morbidity. It is defined as a convulsive seizure lasting more than 5 min or consecutive seizures without recovery of consciousness. Successful management of CSE depends on rapid administration of adequate doses of anti-epileptic drugs (AEDs). The exact choice of AED is less important than rapid treatment and early consideration of reversible etiologies. Current guidelines recommend the use of benzodiazepines (BNZ) as first-line treatment in CSE. Midazolam is effective and safe in the pre-hospital or home setting when administered intramuscularly (best evidence), buccally, or nasally (the latter two possibly faster acting than intramuscular (IM) but with lower levels of evidence). Regular use of home rescue medications such as nasal/buccal midazolam by patients and caregivers for prolonged seizures and seizure clusters may prevent SE, prevent emergency room visits, improve quality of life, and lower health care costs. Traditionally, phenytoin is the preferred second-line agent in treating CSE, but it is limited by hypotension, potential arrhythmias, allergies, drug interactions, and problems from extravasation. Intravenous valproate is an effective and safe alternative to phenytoin. Valproate is loaded intravenously rapidly and more safely than phenytoin, has broad-spectrum efficacy, and fewer acute side effects. Levetiracetam and lacosamide are well tolerated intravenous (IV) AEDs with fewer interactions, allergies, and contraindications, making them potentially attractive as second- or third-line agents in treating CSE. However, data are limited on their efficacy in CSE. Ketamine is probably effective in treating refractory CSE (RCSE), and may warrant earlier use; this requires further study. CSE should be treated aggressively and quickly, with confirmation of treatment success with epileptiform electroencephalographic (EEG), as a transition to non-convulsive status epilepticus is common. If the patient is not fully awake, EEG should be continued for at least 24 h. How aggressively to treat refractory non-convulsive SE (NCSE) or intermittent non-convulsive seizures is less clear and requires additional study. Refractory SE (RSE) usually requires anesthetic doses of anti-seizure medications. If an auto-immune or paraneoplastic etiology is suspected or no etiology can be identified (as with cryptogenic new onset refractory status epilepticus, known as NORSE), early treatment with immuno-modulatory agents is now recommended by many experts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Trinka E et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23. Comprehensive review of seizure types and definitions by world experts.

    Article  PubMed  Google Scholar 

  2. DeLorenzo RJ et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39(8):833–40.

    Article  CAS  PubMed  Google Scholar 

  3. Treiman DM et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.

    Article  CAS  PubMed  Google Scholar 

  4. DeLorenzo RJ et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond. Virginia Neurol. 1996;46(4):1029–35.

    CAS  Google Scholar 

  5. Hesdorffer DC et al. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology. 1998;50(3):735–41.

    Article  CAS  PubMed  Google Scholar 

  6. Logroscino G et al. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia. 2001;42(8):1031–5.

    Article  CAS  PubMed  Google Scholar 

  7. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615–24.

    Article  PubMed  Google Scholar 

  8. Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care. 2014;20(3):476–83.

    Article  PubMed  Google Scholar 

  9. Logroscino G et al. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344–9.

    Article  CAS  PubMed  Google Scholar 

  10. Logroscino G et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46 Suppl 11:46–8.

    Article  PubMed  Google Scholar 

  11. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10(10):922–30.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Foreman B, Hirsch LJ. Epilepsy emergencies: diagnosis and management. Neurol Clin. 2012;30(1):11–41. vii.

    Article  PubMed  Google Scholar 

  13. Belcour D et al. Prevalence and risk factors of stress cardiomyopathy after convulsive status epilepticus in ICU patients. Crit Care Med. 2015;43(10):2164–70.

    Article  PubMed  Google Scholar 

  14. Kalviainen R. Intranasal therapies for acute seizures. Epilepsy Behav. 2015;49:303–6.

    Article  PubMed  Google Scholar 

  15. Manno EM et al. Cardiac pathology in status epilepticus. Ann Neurol. 2005;58(6):954–7.

    Article  PubMed  Google Scholar 

  16. Vooturi S et al. Prognosis and predictors of outcome of refractory generalized convulsive status epilepticus in adults treated in neurointensive care unit. Clin Neurol Neurosurg. 2014;126:7–10.

    Article  PubMed  Google Scholar 

  17. Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci. 1997;17(19):7532–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Hillman J et al. Clinical significance of treatment delay in status epilepticus. Int J Emerg Med. 2013;6(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Alldredge BK et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631–7.

    Article  CAS  PubMed  Google Scholar 

  20. Brophy GM et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23. Provides the standard evidence based guidelines in managing SE, from the Neurocritical Care Society.

    Article  PubMed  Google Scholar 

  21. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802–18.

    Article  PubMed  Google Scholar 

  22. Silbergleit R et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591–600. Provides class 1 evidence supporting treatment of SE with IM midazolam. Underscores the importance of rapid administration of anti-epileptic medications.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–8. A prospective, randomized study pitting lorazepam versus levetiracetam as first line treatment of SE. Authors found levetiracetam to be similiarly effective as lorazepam. This study needs to be replicated.

    Article  CAS  PubMed  Google Scholar 

  24. Gillies D et al. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev. 2005;4:CD003079.

    PubMed  Google Scholar 

  25. Ameer B, Greenblatt DJ. Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. Drugs. 1981;21(3):162–200.

    Article  CAS  PubMed  Google Scholar 

  26. Leppik IE et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249(11):1452–4.

    Article  CAS  PubMed  Google Scholar 

  27. Verrotti A et al. The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure. 2015;31:49–55.

    Article  PubMed  Google Scholar 

  28. Brigo F et al. A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs. 2015;29(9):741–57.

    Article  PubMed  Google Scholar 

  29. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 1998;26(5):947–56.

    Article  CAS  PubMed  Google Scholar 

  30. Zhou Y et al. Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study. Crit Care. 2014;18(3):R122.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy. 2007;27(3):389–98.

    Article  CAS  PubMed  Google Scholar 

  32. Devlin JW, Mallow-Corbett S, Riker RR. Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S231–43.

    Article  CAS  PubMed  Google Scholar 

  33. De Winter S et al. Impact of temperature exposure on stability of drugs in a real-world out-of-hospital setting. Ann Emerg Med. 2013;62(4):380–7. e1.

    Article  PubMed  Google Scholar 

  34. Welch RD et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia. 2015;56(2):254–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Arya R et al. Efficacy of nonvenous medications for acute convulsive seizures: a network meta-analysis. Neurology. 2015;85(21):1859–68. Interesting analysis of available non-venous treatment modalities for acute convulsive seizures. Adds to the building evidence supporting the use of intranasal or buccal midazolam in this setting.

    Article  CAS  PubMed  Google Scholar 

  36. Brigo F et al. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav. 2015;49:325–36.

    Article  PubMed  Google Scholar 

  37. Inokuchi R et al. Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: a retrospective cohort study. Medicine (Baltimore). 2015;94(7):e555.

    Article  CAS  Google Scholar 

  38. Gibbons RJ et al. American College of Cardiology/American Heart Association clinical practice guidelines: part I: where do they come from? Circulation. 2003;107(23):2979–86.

    Article  PubMed  Google Scholar 

  39. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2006;67(2):340–2.

    Article  CAS  PubMed  Google Scholar 

  40. Agarwal P et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527–32.

    Article  PubMed  Google Scholar 

  41. Chakravarthi S et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–63.

    Article  CAS  PubMed  Google Scholar 

  42. Malamiri RA et al. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16(5):536–41.

    Article  PubMed  Google Scholar 

  43. Mundlamuri RC et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam—pilot study. Epilepsy Res. 2015;114:52–8.

    Article  CAS  PubMed  Google Scholar 

  44. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23(3):167–74. Interesting meta-analysis with strict inclusion criteria. Authors concluded that phenytoin should not be considered before valproic acid, levetiracetam and phenobarbital in the treatment of RSE.

    Article  PubMed  Google Scholar 

  45. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553–64.

    Article  CAS  PubMed  Google Scholar 

  46. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802.

    Article  CAS  PubMed  Google Scholar 

  47. Frend V, Chetty M. Dosing and therapeutic monitoring of phenytoin in young adults after neurotrauma: are current practices relevant? Clin Neuropharmacol. 2007;30(6):362–9.

    Article  PubMed  Google Scholar 

  48. Cook AM et al. Practice variations in the management of status epilepticus. Neurocrit Care. 2012;17(1):24–30.

    Article  PubMed  Google Scholar 

  49. Kay HY et al. M-current preservation contributes to anticonvulsant effects of valproic acid. J Clin Invest. 2015;125(10):3904–14.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Alvarez V et al. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292–6.

    Article  CAS  PubMed  Google Scholar 

  51. Limdi NA et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;64(2):353–5.

    Article  CAS  PubMed  Google Scholar 

  52. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–38.

    Article  CAS  PubMed  Google Scholar 

  53. Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008;33(5):513–9.

    Article  CAS  PubMed  Google Scholar 

  54. Hernandez-Diaz S et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9.

    Article  CAS  PubMed  Google Scholar 

  55. Brigo F et al. IV Valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19(9):1180–91.

    Article  CAS  PubMed  Google Scholar 

  56. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69(3):273–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Garcia-Perez E et al. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking. Epilepsia. 2015;56(4):535–45.

    Article  CAS  PubMed  Google Scholar 

  58. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.

    Article  CAS  PubMed  Google Scholar 

  59. Atmaca MM et al. Intravenous levetiracetam treatment in status epilepticus: a prospective study. Epilepsy Res. 2015;114:13–22.

    Article  CAS  PubMed  Google Scholar 

  60. Loscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53 Suppl 8:12–25.

    Article  PubMed  CAS  Google Scholar 

  61. Bledsoe KA, Kramer AH. Propylene glycol toxicity complicating use of barbiturate coma. Neurocrit Care. 2008;9(1):122–4.

    Article  PubMed  Google Scholar 

  62. Brigo F et al. A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. Epileptic Disord. 2013;15(3):314–23.

    PubMed  Google Scholar 

  63. Rogawski MA et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189–205.

    Article  CAS  PubMed  Google Scholar 

  64. Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs. 2009;69(4):449–59.

    Article  CAS  PubMed  Google Scholar 

  65. Kropeit D et al. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers. Acta Neurol Scand. 2015;132(5):346–54.

    Article  CAS  PubMed  Google Scholar 

  66. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393–404.

    Article  PubMed  CAS  Google Scholar 

  67. Kellinghaus C, Berning S, Stogbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129(5):294–9.

    Article  CAS  PubMed  Google Scholar 

  68. Miro J et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure. 2013;22(1):77–9.

    Article  CAS  PubMed  Google Scholar 

  69. Husain A. The TRENdS trial: Intravenous lacosamide versus fosphenytoin for the treatment of frequent nonconvulsive seizures in critically ill patients. Late breaking abstract American Epilepsy Society 2015, 2015.

  70. Moseley BD, Degiorgio CM. Refractory status epilepticus treated with trigeminal nerve stimulation. Epilepsy Res. 2014;108(3):600–3.

    Article  PubMed  Google Scholar 

  71. Rossetti AO. Which anesthetic should be used in the treatment of refractory status epilepticus? Epilepsia. 2007;48 Suppl 8:52–5.

    Article  PubMed  Google Scholar 

  72. Fernandez A et al. High-dose midazolam infusion for refractory status epilepticus. Neurology. 2014;82(4):359–65. Provides evidence supporting high dose midazolam in treating RSE. Showed better outcomes in the high dose midazolam group, and shed light on the safety profile at such high doses.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639–49.

    Article  CAS  PubMed  Google Scholar 

  74. Matta JA et al. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci U S A. 2008;105(25):8784–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Robinson BJ et al. Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? Anesthesiology. 1997;86(1):64–72.

    Article  CAS  PubMed  Google Scholar 

  76. Bayrlee A et al. Treatment of super-refractory status epilepticus. Curr Neurol Neurosci Rep. 2015;15(10):66.

    Article  PubMed  CAS  Google Scholar 

  77. Yan J, Jiang H. Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain. J Neurosurg Anesthesiol. 2014;26(2):155–60.

    Article  PubMed  Google Scholar 

  78. Gaspard N et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–503. Although retrospective, this large multicenter study found ketamine to be relatively safe and somewhat effective for treating RSE.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Ilvento L et al. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsy Behav. 2015;49:343–6.

    Article  PubMed  Google Scholar 

  80. Zeiler FA et al. Lidocaine for status epilepticus in adults. Seizure. 2015;31:41–8.

    Article  CAS  PubMed  Google Scholar 

  81. Achar S, Kundu S. Principles of office anesthesia: part I. Infiltrative anesthesia. Am Fam Physician. 2002;66(1):91–4.

    PubMed  Google Scholar 

  82. Peixoto RD, Hawley P. Intravenous lidocaine for cancer pain without electrocardiographic monitoring: a retrospective review. J Palliat Med. 2015;18(4):373–7.

    Article  PubMed  Google Scholar 

  83. Forrence E, Covinsky JO, Mullen C. A seizure induced by concurrent lidocaine-tocainide therapy—is it just a case of additive toxicity? Drug Intell Clin Pharm. 1986;20(1):56–9.

    CAS  PubMed  Google Scholar 

  84. Gaspard N et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13. Reviews the clinical features of NORSE and highlights its diverse etiologies, especially autoimmune.

    Article  PubMed  Google Scholar 

  85. Khawaja AM et al. New-onset refractory status epilepticus (NORSE)—the potential role for immunotherapy. Epilepsy Behav. 2015;47:17–23.

    Article  PubMed  Google Scholar 

  86. Lopinto-Khoury C, Sperling MR. Autoimmune status epilepticus. Curr Treat Options Neurol. 2013;15(5):545–56.

    Article  PubMed  Google Scholar 

  87. Broomall E et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol. 2014;76(6):911–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hottinger A et al. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26(9):761–72.

    Article  CAS  PubMed  Google Scholar 

  89. Asadi-Pooya AA et al. Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings. Seizure. 2015;24:114–7.

    Article  PubMed  Google Scholar 

  90. Rohracher A et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav. 2015;49:354–8.

    Article  CAS  PubMed  Google Scholar 

  91. Redecker J et al. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav. 2015;45:176–9.

    Article  PubMed  Google Scholar 

  92. Rantsch K et al. Treatment and course of different subtypes of status epilepticus. Epilepsy Res. 2013;107(1–2):156–62.

    Article  CAS  PubMed  Google Scholar 

  93. Alvarez V et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia. 2015;56(8):1275–85.

    Article  CAS  PubMed  Google Scholar 

  94. Shangguan Y, Liao H, Wang X. Clonazepam in the treatment of status epilepticus. Expert Rev Neurother. 2015;15(7):733–40.

    Article  CAS  PubMed  Google Scholar 

  95. Zeiler FA et al. Magnesium sulfate for non-eclamptic status epilepticus. Seizure. 2015;32:100–8.

    Article  CAS  PubMed  Google Scholar 

  96. Zeiler FA et al. Modern inhalational anesthetics for refractory status epilepticus. Can J Neurol Sci. 2015;42(2):106–15.

    Article  PubMed  Google Scholar 

  97. Sivakumar S et al. Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia. 2015;56(6):e83–9.

    Article  CAS  PubMed  Google Scholar 

  98. Shekh-Ahmad T et al. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 2015;49:298–302.

    Article  PubMed  Google Scholar 

  99. Spampanato J, Dudek FE. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia. 2014;55(9):e94–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Zeiler FA et al. Therapeutic hypothermia for refractory status epilepticus. Can J Neurol Sci. 2015;42(4):221–9.

    Article  PubMed  Google Scholar 

  101. Zeiler FA et al. VNS for refractory status epilepticus. Epilepsy Res. 2015;112:100–13.

    Article  CAS  PubMed  Google Scholar 

  102. Lhatoo SD, Alexopoulos AV. The surgical treatment of status epilepticus. Epilepsia. 2007;48 Suppl 8:61–5.

    Article  PubMed  Google Scholar 

  103. Alexopoulos A et al. Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis. Neurology. 2005;64(3):567–70.

    Article  CAS  PubMed  Google Scholar 

  104. Bhatia S et al. Surgical treatment of refractory status epilepticus in children: clinical article. J Neurosurg Pediatr. 2013;12(4):360–6.

    Article  PubMed  Google Scholar 

  105. Caraballo RH et al. Ketogenic diet in pediatric patients with refractory focal status epilepticus. Epilepsy Res. 2014;108(10):1912–6.

    Article  PubMed  Google Scholar 

  106. Thakur KT et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82(8):665–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, PO Box 208018, New Haven, CT, 06520-8018, USA

    Eric H. Grover MD & Lawrence J. Hirsch MD

  2. SSM St. Mary Health Center, 1035 Bellevue suite 500, St. Louis, MO, 63117, USA

    Yara Nazzal MD

Authors
  1. Eric H. Grover MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yara Nazzal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence J. Hirsch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence J. Hirsch MD.

Ethics declarations

Conflict of Interest

Eric H. Grover and Yara Nazzal declare that they have no conflict of interest.

Lawrence J. Hirsch has received research support from UCB, Upsher-Smith, Lundbeck, Eisai, Sunovion, and Acorda. Dr. Hirsch also has received consultation fees from Upsher-Smith, Marinus, Monteris, and Sunovion as well as speaking honoraria from Neuropace.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Epilepsy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grover, E.H., Nazzal, Y. & Hirsch, L.J. Treatment of Convulsive Status Epilepticus. Curr Treat Options Neurol 18, 11 (2016). https://doi.org/10.1007/s11940-016-0394-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-016-0394-5

Keywords

Search

Navigation